Rheumatoid arthritis Musculoskeletal Diseases Rheumatoid arthritis (RA)
Conditions
Interventions
Intra-articular injection of
1. 25 mg Etanercept
2. 40 mg methylprednisolone
Sponsors
The Parker Institute (Denmark)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Rheumatoid arthritis (RA), age >18 years, written informed consent, flare of RA in wrist, elbow, or knee joint
Exclusion criteria
Exclusion criteria: Systemic anti tumour necrosis factor (TNF) alpha therapy, had had intra-articular injection of steroids in the joint within 3 months, had skin lesions or other disease associated with increased risk of infection after injection, malignancy, severe heart, kidney, and/or lung disease, infections including human immunodeficiency virus (HIV), elevated alanine aminotransferase (ALT) (twice above the reference range), creatinine (>175 mmol/l), leucopenia (<3.5 x 10^9/l), thrombocytopenia (<125 x 10^9/l), or hemoglobin <8.5 g/dl, or allergy to the injected compounds. Women were excluded if pregnant, or of childbearing potential with an unacceptable birth control method.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Patient global evaluation of the joint treated 2. Independent joint evaluation by investigator | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical: Joint score for swelling and tenderness and HAQ, CRP, ESR, grip strength Imaging: Ultrasound Doppler pixel fraction Ultrasound Doppler RI Postcontrast magnetic resonance imaging (MRI) | — |
Countries
Denmark
Outcome results
None listed